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REVIEW
Abstract: Acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB),
and community-acquired pneumonia (CAP) are common conditions and constitute a substantial
socioeconomic burden. The ketolides are a new class of antibacterials with a targeted spectrum
of antibacterial activity. In vitro, telithromycin is active against common bacterial pathogens
that cause upper and lower respiratory tract infections, including some isolates that are resistant
to other antibiotic classes. In 2004, telithromycin was the first ketolide antibiotic approved
for clinical use by the US Food and Drug Administration for the treatment of adult outpatients
with ABS, AECB, and mild-to-moderate CAP. This review discusses the use of telithromycin
in the treatment of these infections, providing an overview of its antibacterial activity,
pharmacokinetic and pharmacodynamic properties, clinical efficacy, and tolerability–safety,
and concludes that telithromycin is an appropriate option for the treatment of community-
acquired ABS, AECB, and mild-to-moderate CAP.
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Introduction
Acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB),
and community-acquired pneumonia (CAP) are common conditions and constitute a
substantial socioeconomic burden. Lower respiratory tract infections (RTIs), such as
CAP and AECB, represent a particular public health concern owing to the morbidity
and mortality associated with these infections (Niederman et al 1998, 1999; Bartlett
et al 2000).
Bacterial pathogens associated with RTIs include Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis, and atypical–intracellular
organisms such as Mycoplasma pneumoniae, Chlamydophila (Chlamydia)
pneumoniae, and Legionella pneumophila. Antibacterial treatment of outpatient
community-acquired RTIs is usually empiric, since the causative pathogen is rarely
identified before initiation of antibacterial therapy. However, the development and
spread of antibacterial resistance among respiratory pathogens, in particular S.
pneumoniae, now represents a key challenge in the management of RTIs (File 2004).
Although the clinical impact of bacterial resistance is still under debate, there have
been a number of recent cases of treatment failure associated with macrolide use
(Rzeszutek et al 2004; Klugman and Lonks 2005).
The ketolides are a new class of antibacterials with a targeted spectrum of
antibacterial activity. In vitro, telithromycin is active against common bacterial
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pathogens that cause upper and lower RTIs, including some
isolates resistant to other antibiotic classes. In 2004,
telithromycin was the first ketolide antibiotic approved for
clinical use by the US Food and Drug Administration for
the treatment of adult outpatients with ABS, AECB, and
mild-to-moderate CAP.
This review discusses the use of telithromycin in the
treatment of these infections, providing an overview of
its antibacterial activity, pharmacokinetic and pharmaco-
dynamic properties, clinical efficacy, and tolerability–
safety.
Chemistry of telithromycin
The ketolide class of antibacterials, of which telithromycin
is the first to be approved for clinical use, are semisynthetic
derivatives of the 14-membered macrolide, erythromycin.
Telithromycin retains the macrolactone ring structure and
the D-desosamine sugar attached at position 5 (Figure 1).
The defining characteristic of the ketolides is the removal
of the neutral sugar, Lcladinose, from the 3 position of the
erythronolide ring and the subsequent oxidation of the
3hydroxyl to a 3-keto functional group (Figure 1). Removal
of the Lcladinose moiety improves the acid stability of
telithromycin. Furthermore, compounds with the 3-keto
group do not trigger the expression of resistance to MLSB
(macrolide–lincosamide–streptograminB) antibacterials in
strains with inducible erm determinants (Bonnefoy et al
1997). This allows telithromycin to remain active against
bacterial strains in which MLSB resistance would be induced
(Bonnefoy et al 1997).
The 11, 12-carbamate present in telithromycin (Figure 1)
enhances the activity of ketolides (Douthwaite and
Champney 2001) and, together with the 6-O-alkyl group,
prevents 6–9 or 9–12 cyclization of the compound, which
would result in the formation of unstable hemiketal products
(commonly formed by erythromycin). Telithromycin also
contains heterocyclic aromatic rings spaced from the lactone
ring structure via short alkyl or allyl linkages. These
structures impart improved ribosomal binding and thereby
increase the activity of the compounds against both
macrolide-susceptible and macrolide-resistant strains
(Mankin et al 2000).
Mechanism of action
Telithromycin inhibits bacterial protein synthesis by
interacting close to the peptidyl transferase site of the 50S
ribosomal subunit (Champney and Tober 2001); the main
sites of macrolide and ketolide interaction are within
domains II and V of the 23S ribosomal RNA (Hansen et al
1999; Xiong et al 1999). Ketolides bind to the ribosome in
a 1:1 ratio (Hansen et al 1999), indicating that domains II
and V of the 23S rRNA lie in close proximity within the
tertiary structure of the rRNA and form a single drug-binding
pocket. This structure has been confirmed by crystallo-
graphic models of the 50S subunit (Ban et al 2000;
Schlunzen et al 2001).
Chemical footprinting experiments have located the main
site of ketolide and macrolide interaction at nucleotides
A2058 and A2059 in domain V (Hansen et al 1999; Xiong
et al 1999). Although both macrolides and ketolides protect
these bases from chemical modification, the ketolides
display a higher affinity than macrolides for forming
interactions with the ribosomes (Bertho et al 1998;
Capobianco et al 2000). This increased affinity has been
shown to be caused by the additional interaction at A752 in
domain II and is mediated by the 11, 12-carbamate side
chain and alkyl or allyl linkages (Hansen et al 1999). Base
substitutions at position A752 reduce the binding of
ketolides, supporting the notion that the adenine base at
Figure 1 Chemical structure of telithromycin.Therapeutics and Clinical Risk Management 2006:2(1) 61
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A752 is an important secondary contact site for the
carbamate ketolides (Novotny et al 2001). This additional
contact presumably enables the ketolides to retain activity
against bacteria that have base modifications in domain V
(Capobianco et al 2000; Douthwaite et al 2000; Bemer-
Melchior et al 2000).
Mechanism of resistance
The main factor behind the development of the ketolides
was the need for new antibacterials to overcome the problem
of macrolide resistance among the common respiratory tract
pathogens, particularly S. pneumoniae. The most common
macrolide resistance mechanisms in Gram-positive bacteria
involve drug efflux and target modification (Leclercq and
Courvalin 1991; Sutcliffe et al 1996). Efflux resistance in
S. pneumoniae and Streptococcus pyogenes is encoded by
the mef(A) gene. Target modification involves methylation
of the key A2058 nucleotide in the MLSB antibiotic binding
site on the ribosome by methylases encoded by erm(B) in
S. pneumoniae, and erm(B) and erm(TR) in S. pyogenes
(Bonnefoy et al 1997; Roberts et al 1999). The L-cladinose
moiety present in macrolides contributes to the strong
induction of erm(B) resistance by these agents. Other less
common macrolide resistance mechanisms include
mutations in the ribosomal proteins or 23S rRNA (Tait-
Kamradt et al 2000).
Telithromycin is active against bacterial strains
expressing mef(A) resistance (Schito et al 2004; Jenkins et
al 2005), most likely because telithromycin is a poor
substrate for the macrolide efflux pump (Leclercq 2000).
Telithromycin also retains activity against pneumococcal
isolates that constitutively express the erm(B) resistance
gene (Schito et al 2004; Jenkins et al 2005). Furthermore,
the lack of an L-cladinose group ensures that telithromycin
does not induce erm expression and is thereby active against
strains inducibly resistant to macrolides (Mauvais and
Bonnefoy 2000).
Selection experiments have shown that exposure of
pneumococci to telithromycin is less likely to result in
development of resistance than exposure to macrolides
(Fernandez-Roblas et al 1999; Davies et al 2000; Edlund et
al 2000). Typically, exposure to telithromycin resulted in
minimal increases in minimum inhibitory concentration
(MIC) values, with mutations occurring at lower frequencies
than those obtained for macrolides under the same
conditions (Davies et al 2000).
In vitro activity
Results from a number of early in vitro studies confirmed
that telithromycin possesses potent activity against both
common and atypical–intracellular respiratory pathogens
(Biedenbach et al 1998; Pankuch, Hoellman, et al 1998;
Roblin and Hammerschlag 1998; Bébéar et al 2000). Table 1
summarizes the activity of telithromycin and macrolide
antibacterials against key respiratory pathogens collected
in the USA (2001–2002) from patients with community-
acquired RTIs as part of the PROTEKT US (Prospective
Resistant Organism Tracking and Epidemiology for the
Ketolide Telithromycin in the United States) longitudinal
surveillance study. In this study, telithromycin was more
active against S. pneumoniae, including both penicillin-
resistant and macrolide-resistant strains, than the macrolides
(Table 1) (Brown and Rybak 2004). Recently published data
from PROTEKT US (2002–2003) demonstrate that MIC90
values for some macrolides against S. pneumoniae increased
considerably between 2001 and 2002, and 2002 and 2003;
the MIC90 for erythromycin changed from 16 µg/mL to
64 µg/mL and the azithromycin MIC90 increased from
32 µg/mL to ≥ 256 µg/mL. Overall, > 99% of isolates were
susceptible to telithromycin, and telithromycin susceptibility
was unaffected by reduced susceptibility of these isolates
to penicillin and/or erythromycin (Brown and Rybak 2004).
Telithromycin is also active against Gram-negative
respiratory tract bacteria, such as H. influenzae, and is not
affected by β−lactamase production (Table 1), making it
active against ampicillin-resistant strains of these pathogens
(Brown and Rybak 2004). Similar results confirming the
activity of telithromycin against respiratory pathogens have
been demonstrated in the PROTEKT global surveillance
study (Kohno et al 2003; Farrell and Felmingham 2004;
Reinert, Felmingham, et al 2004).
Telithromycin also shows in vitro activity against less
common respiratory pathogens including methicillin
(oxacillin)-susceptible Staphylococcus aureus (MIC90
≤ 0.25 mg/mL) (Barry et al 1998; Boswell, Andrews, Ashby,
et al 1998) and atypical–intracellular respiratory pathogens,
including M. pneumoniae and C. pneumoniae (Roblin and
Hammerschlag 1998; Bébéar et al 2000). In addition,
telithromycin has minimal activity against a range of Gram-
negative nonrespiratory pathogens and commensal bacteria,
including Acinetobacter spp., Enterobacteriaceae spp.,
Vibrio spp., Campylobacter jejuni, Aeromonas hydrophila,
Plesiomonas shigelloides, and Pseudomonas aeruginosa
(Felmingham and Farrell 2006).Therapeutics and Clinical Risk Management 2006:2(1) 62
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Pharmacokinetics
Absorption
Following first-pass metabolism of telithromycin by the
liver and the gastrointestinal tract, the absolute
bioavailability of this agent (which is unaffected by the
age of the subject) is ~57% (Perret et al 2002). Neither
the rate nor the extent of absorption of telithromycin is
affected by food intake, meaning that the drug can be
taken without regard to mealtimes (Bhargava, Lenfant,
et al 2002). Administration of telithromycin 800 mg once
daily for 7 days to healthy volunteers resulted in rapid
absorption: the mean peak serum concentration (Cmax)
of 2.27 μg/mL was reached within 1 hour of dosing
(Namour et al 2001).
Distribution
Telithromycin is subject to moderate serum protein binding;
approximately 60%–70% is protein-bound, mainly to
albumin and α1-acid glycoprotein. Studies investigating the
tissue distribution of telithromycin indicate that the drug
penetrates effectively into respiratory tissues and fluids.
Dosing of telithromycin 800 mg once daily for 5 days
produced high concentrations of the drug in broncho-
pulmonary tissue and fluid, including alveolar macrophages
and epithelial lining fluid (Muller-Serieys et al 2001, 2004;
Khair et al 2001). In addition, telithromycin concentrates
in other tissues and fluids as shown in Table 2. Drug
concentrations at these sites exceeded the peak concentration
of the drug in plasma and remained above telithromycin
MICs for key respiratory pathogens throughout the 24-hour
administration period.
Metabolism and excretion
Overall, approximately 70% of the administered dose of
telithromycin is metabolized (33% pre-systemic and 37%
systemic), approximately half of which occurs in the liver
via the cytochrome P450 3A4 (CYP3A4) pathway. Of the
57% of administered drug that reaches the systemic
circulation unchanged, 13% is excreted unchanged in urine,
7% is excreted unchanged in the feces, and 37% is
metabolized by the liver (Sultan et al 1999; Aventis 2003).
Telithromycin has a biphasic half-life, with an overall
terminal half-life of ~10 hours and renal clearance of
12.5 L/hour (Namour et al 2001). No dosage adjustment is
required in patients with mild-to-moderate renal impairment
or in patients with mild, moderate, or severe hepatic
impairment.
Pharmacodynamics
Telithromycin exhibits bactericidal activity against S.
pneumoniae, including isolates resistant to erythromycin
(Pankuch, Visalli, et al 1998). Telithromycin also
demonstrates limited bactericidal activity against S.
pyogenes, H. influenzae, and M. catarrhalis by 24 hours,
depending upon the concentration of antibiotic (typically
≥ 4 times the MIC value is required) and the size of the
inoculum (Boswell, Andrews, Wise, et al 1998; Pankuch,
Hoellman, et al 1998; Pankuch, Visalli, et al 1998; Odenholt
Table 1  In vitro activities of telithromycin, erythromycin, and azithromycin against key respiratory pathogens collected in the USA
as part of the PROTEKT US study 2001–2002a
                  Telithromycin                  Erythromycin               Azithromycin
MIC90 Range MIC90 Range MIC90 Range
Organism (μg/mL) (μg/mL) %S (μg/mL) (μg/mL) %S (μg/mL) (μg/mL) %S
Streptococcus pneumoniae
All (n = 10,012) 0.25 ≤ 0.015–4 99.9 16 ≤  0.06–> 256 71.9 32 ≤ 0.03–> 256 71.9
Pen-I (n = 1424)
b 0.25 ≤ 0.015–2 99.9 > 256 ≤  0.06–> 256 50.1 > 256 ≤ 0.03–> 256 50.2
Pen-R (n = 2124)c 0.5 ≤ 0.015–4 99.4 > 256 ≤  0.06–> 256 19.4 > 256 ≤ 0.03–> 256 19.6
Ery-R (n = 2793)
d 0.5 ≤ 0.015–4 99.5 > 256 1–> 256 0 > 256 0.5–> 256 0.1
Pen-R and Ery-R (n = 1709) 1 ≤ 0.015–4 99.3 > 256 1–> 256 0 > 256 0.5–> 256 0.2
Haemophilus influenzae
All (n = 3296) 4 ≤ 0.12–>16 96.3 ND ND ND 2 ≤ 0.12–> 256 98.9
β-lactamase positive (n = 905) 4 ≤ 0.12–>16 97.3 ND ND ND 2 ≤ 0.12–128 99.2
β-lactamase negative (n = 2391) 4 ≤ 0.12–>16 95.9 ND ND ND 2 ≤ 0.12–> 256 98.8
Streptococcus pyogenes (n = 4508) 0.03 ≤ 0.015–16 — 0.12 ≤ 0.06–> 256 94.0 0.25 ≤ 0.03–> 256 94.1
aAdapted from Brown and Rybak (2004).
bPen-I, penicillin-intermediate (MIC 0.12–1 μg/mL).
cPen-R, penicillin-resistant (MIC ≥ 2 μg/mL).
dEry-R, erythromycin-resistant (MIC ≥ 1 μg/mL).
Abbreviations: MIC, minimum inhibitory concentration; ND, not determined; S, susceptible.Therapeutics and Clinical Risk Management 2006:2(1) 63
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et al 2001). In vitro pharmacodynamic models that simulate
human unbound plasma or epithelial lining fluid
concentrations of telithromycin have shown that this agent
rapidly eradicates both macrolide-susceptible and
macrolide-resistant S. pneumoniae (regardless of resistance
phenotype) at concentrations likely to be achieved in vivo
(Zhanel et al 2004, 2005).
An additional consideration when optimizing the dosing
schedule of antibiotics is the post-antibiotic effect (PAE), a
measure of the agent’s continued antibacterial activity after
its removal from the medium. Telithromycin has
demonstrated PAE values equal to or greater than those of
macrolide comparators (Boswell, Andrew, Ashby, et al 1998;
Dubois and St-Pierre 2000; Odenholt et al 2001).
In vivo animal models have confirmed that the
antibacterial activity of telithromycin is concentration-
dependent and that area under the plasma drug
concentration–time curve (AUC) divided by the in vitro MIC
of the agent against the organism in question (AUC/MIC)
is the pharmacodynamic variable most correlated with
efficacy (Bermudez et al 2000; Bonnefoy et al 2001). In
adult patients with CAP treated with telithromycin 800 mg
once daily for 7–10 days, a pharmacodynamic analysis has
explored the relationships between predictor variables
(including AUC/MIC) and microbiologic outcome for the
three major CAP pathogens (S. pneumoniae, H. influenzae,
and S. aureus) (Shi, Pfister, et al 2005). Results from this
analysis showed that the probability of cure following
treatment with telithromycin in adults with CAP was
consistently in the region of 90% across the observed range
of AUC/MIC values for each pathogen, providing
confirmation that the 800 mg once-daily telithromycin dose
exhibits near-maximal antimicrobial activity against S.
pneumoniae, H. influenzae, and S. aureus in patients with
CAP.
Clinical trials
The clinical efficacy and tolerability of telithromycin 800 mg
once daily in adults with ABS, AECB, or mild-to-moderate
CAP have been evaluated in 16 multicenter trials
(summarized in Table 3).
The trials included analysis of both the intent to treat
(ITT) population (mITT = modified intent to treat; any
patient enrolled in the study who received at least 1 dose of
antibiotic) and the per-protocol (PP) population. In most
studies, the primary efficacy endpoint was clinical outcome
in the clinically evaluable per-protocol (PPc) population at
the test of cure (TOC) visit (Days 17–24). Clinical cure was
defined as improvement in signs and symptoms or a return
to pre-infection state without the need for additional
antimicrobials. The bacteriologic eradication rate at TOC
was also recorded for those patients with a causative
pathogen isolated at baseline. Satisfactory bacteriologic
outcome was defined as the eradication or presumed
eradication of the causative pathogen in the bacteriologically
evaluable PP or mITT populations (PPb and bmITT
populations, respectively).
Table 2  Tissue distribution of telithromycin 24 hours after administration of final dose
Mean tissue/fluid/
cell to plasma
Target tissue/fluid/cell Dose regimen concentration ratio Reference
Multiple-dose studies
   White blood cells 600 mg once daily for 10 days 1383 Pham Gia et al (1999)
   Alveolar macrophages 800 mg once daily for 5 days 2160 Khair et al (2001)
   Epithelial lining fluid 800 mg once daily for 5 days 14.41 Khair et al (2001)
   Bronchial mucosa 800 mg once daily for 5 days 12.11 Khair et al (2001)
   Tonsillar tissue 800 mg once daily for 5 days 13.10 Gehanno et al (2003)
   Saliva 800 mg once daily for 10 days 1.60a Edlund et al (2000)
   Sputum 600 mg once daily for 7 days 4.80 Watanuki et al (2001)
Single-dose studies
   Sinus fluid 600 mg dose administered 3–6 hours 4.00 Miyamoto et al (2000)
before tissue collection
   Middle-ear fluid 600 mg dose administered 3–6 hours 2.40 Miyamoto et al (2000)
before tissue collection
aResults reported as a ratio of AUCsaliva/AUCplasma.
Abbreviations: AUC, area under the concentration–time curve.Therapeutics and Clinical Risk Management 2006:2(1) 64
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Acute bacterial sinusitis
Telithromycin has been evaluated for the treatment of ABS
in 4 randomized clinical trials, 3 of which were double-
blinded comparative trials (Table 3) (Roos et al 2002;
Buchanan et al 2003; Luterman et al 2003; Ferguson et al
2004). A diagnosis of ABS was based on radiologic findings
(total sinus opacity and/or air–fluid levels and/or mucosal
thickening) accompanied by ≥ 1 clinical symptom (purulent
nasal discharge; maxillary tenderness–toothache; maxillary
pain on percussion; facial pain, pressure or tightness; or
nasal congestion) of < 28 days’ duration. Patients with
recurrent (> 3 episodes in the previous year) or chronic
(symptoms lasting > 28 days) sinusitis were excluded from
all 3 studies.
In the first trial by Roos et al (2002), a 5-day course of
telithromycin 800 mg once daily was compared with a 10-
day course. Both treatment durations were found to result
in comparable clinical success rates, with 91.1% cure in the
5-day treatment group (PPc population) vs 91.0% cure in
the 10-day treatment group (cure rates in the mITT
populations were 82.6% and 87.5% in the 5-day and 10-
day groups, respectively). Bacteriologic outcomes were also
comparable between treatment groups: a satisfactory
bacteriologic outcome was achieved in 92.9% of patients
treated for 5 days and in 89.9% of patients who received
the 10-day treatment course. These results led the authors
to conclude that a 5-day course of telithromycin 800 mg
once daily would be effective in the treatment of ABS, and
may result in better patient compliance when compared with
10-day treatment courses.
In a second trial (Luterman et al 2003), telithromycin
800 mg for 5 days was compared with telithromycin 800 mg
for 10 days and to amoxicillin–clavulanate 500 mg/125 mg
3 times daily for 10 days. Per-protocol clinical cure rates
were equivalent for all 3 treatment modalities (75.3% for
5-day telithromycin, 72.9% for 10-day telithromycin, and
74.5% for 10-day amoxicillin–clavulanate). In both the
5-day and 10-day telithromycin treatment groups, a
satisfactory bacteriologic outcome was achieved in 6/7
patients, whereas 8/10 comparator-treated patients recorded
a satisfactory bacteriologic outcome.
A 5-day course of once-daily telithromycin was also
shown to be as clinically effective as a 10-day course of
cefuroxime axetil 250 mg twice daily (Buchanan et al 2003).
Per-protocol clinical cure rates for telithromycin and
cefuroxime axetil were 85.2% and 82.0%, respectively, and
84.0% of telithromycin-treated patients vs 79.6% of
comparator-treated patients achieved a satisfactory
bacteriologic outcome (Table 3). The fourth trial (Study
4017; Ferguson et al 2004) demonstrated that a 5-day
telithromycin regimen provides equivalent clinical and
bacteriologic efficacy to 10 days’ treatment with the
fluoroquinolone moxifloxacin (400 mg once daily).
Pooled clinical cure rates from 3 of these studies (Studies
3002, 3005, and 3011) were 80.9% (271/355) for patients
treated with telithromycin vs 77.4% (175/226) in the
comparator-treated group (amoxicillin–clavulanate and
cefuroxime axetil) (Roos et al 2005). Clinical cure rates were
also comparable between telithromycin and comparator
antibacterials for patients in subgroups of special interest,
including those with severe infection (as assessed by the
investigator) (81.8% [45/55] vs 77.8% [35/45]), patients
with radiologic findings of total sinus opacity (85.7%
[84/98] vs 76.7% [33/43]), and those with a symptom
duration of ≥ 7 days (81.5% [229/281] vs 78.0% [135/173]).
Across the 3 studies, clinical cure rates by pathogen in
patients who received 5 days of telithromycin treatment
were 90.2% (55/61) for S. pneumoniae, 87.5% (42/48) for
H. influenzae, 92.9% (13/14) for M. catarrhalis, and 94.7%
(18/19) for S. aureus (Roos et al 2005).
Acute exacerbations of chronic
bronchitis
The efficacy of telithromycin 800 mg once daily for 5 days
has been evaluated in a total of 480 patients (PPc population)
in 3 double-blind comparator-controlled trials (Aubier et al
2002; Zervos et al 2003; Fogarty, de Wet, et al 2005)
(Table 3). Patients eligible for entry into the studies included
those with a documented history of chronic bronchitis
(characterized by cough and excessive sputum production
for ≥ 2 consecutive years) and a clinical diagnosis of AECB
based on the presence of increased cough or dyspnea,
increased sputum volume, and increased sputum purulence.
Clinical and bacteriologic efficacy
Aubier and colleagues (2002) reported that a 5-day course
of telithromycin 800 mg once daily was as effective as a
10-day course of amoxicillin–clavulanate 500 mg/125 mg
3 times daily. Clinical cure rates (PPc population) for
telithromycin and amoxicillin–clavulanate were 86.1% and
82.1%, respectively. Among mITT patients, 81.3% of
telithromycin-treated patients achieved clinical cure vs
78.1% of comparator-treated patients. Among PPb patients,
a satisfactory bacteriologic outcome was recorded for 69.2%
of those treated with telithromycin and 70.0% of patients
who received amoxicillin–clavulanate. Re-infections at theTherapeutics and Clinical Risk Management 2006:2(1) 65
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late post-therapy visit (Days 31–36) were slightly more
common for amoxicillin–clavulanate than telithromycin
(9 vs 2).
In the second study, Zervos et al (2003) compared
telithromycin 800 mg once daily for 5 days with cefuroxime
axetil 500 mg twice daily for 10 days. Both treatments
provided equivalent clinical efficacy, with PP cure rates of
86.4% in the telithromycin group and 83.1% in the
cefuroxime axetil group. Among mITT patients, 78.0% of
telithromycin-treated patients and 72.3% of cefuroxime-
treated patients were assessed as clinical cures at the TOC
visit. When causative pathogens were identified, a
satisfactory bacteriologic outcome was achieved in 76.0%
of patients in the telithromycin group vs 78.6% in the
cefuroxime axetil group. Relapses or re-infection occurred
in a small number of patients in both groups at the late post-
therapy visit (10 in the telithromycin group and 8 in the
cefuroxime axetil group).
The third study of telithromycin in patients with AECB
compared the clinical and bacteriologic efficacy of
telithromycin 800 mg once daily for 5 days and
clarithromycin 500 mg twice daily for 10 days (Fogarty, de
Wet, et al 2005). Clinical cure (PP population) was achieved
in 85.8% and 89.2% of telithromycin and clarithromycin
recipients, respectively. Among mITT patients, 83.0% of
telithromycin-treated patients and 83.7% of clarithromycin-
treated patients were assessed as clinical cures. Eradication
(presumed or documented) of the causative pathogen
occurred in 81.9% of telithromycin patients vs 82.9% of
clarithromycin patients.
Overall, an analysis of pooled data from the 3 studies
indicated similar levels of clinical and bacteriologic efficacy
for telithromycin and comparator antibacterials (Fogarty,
Zervos, et al 2005). Per-protocol clinical cure rates at
TOC were 86.0% (413/480) and 85.8% (416/485) for
telithromycin and comparators, respectively, and a
satisfactory bacteriologic outcome was achieved in 77.2%
(105/136) of telithromycin-treated patients and 79.1%
(106/134) of comparator-treated patients. Clinical cure rates
were also comparable between telithromycin and
comparator antibacterials for patients in subgroups of special
interest, including those aged ≥ 65 years (85.3% [157/184]
vs 83.3% [179/215]), patients with significant airway
obstruction (77.1% [64/83] vs 81.4% [79/97]), patients
with severe AECB (as assessed by the investigator) (84.4%
[38/45] vs 75.0% [36/48]), and patients who smoked (86.8%
[190/219] vs 85.4% [169/189]) (Fogarty, Zervos, et al 2005).
Across the 3 studies, clinical cure rates by pathogen in
patients who received 5 days of telithromycin treatment
were 81.5% (22/27) for S. pneumoniae, 73.3% (44/60) for
H. influenzae, and 93.1% (27/29) for M. catarrhalis
(Fogarty, Zervos, et al 2005).
Health outcomes
Healthcare resource utilization (including unscheduled
AECB-related outpatient visits, emergency room [ER] visits,
hospitalizations, and time lost from work) has been
documented in one of the AECB clinical trials (comparing
telithromycin with clarithromycin) (Fogarty, de Wet, et al
2005). Percentages of patients attending an unscheduled
AECB-related ER visit were lower in the telithromycin
group compared with the clarithromycin group (0% vs 2.8%,
respectively), fewer telithromycin-treated patients were
hospitalized owing to AECB (0.4% vs 1.4%, respectively),
and fewer employed telithromycin patients reported days
lost from work (23% vs 31%, respectively) (Fogarty, de
Wet, et al 2005). These differences in healthcare resource
use were estimated to contribute to a direct cost saving of
approximately US$146 per patient.
Community-acquired pneumonia
The efficacy of telithromycin 800 mg for 5 or 7–10 days
has been evaluated in a total of 9 trials involving adult or
adolescent patients with a radiologically confirmed
diagnosis of CAP (Hagberg et al 2002; van Rensburg et al
2002; Carbon, Moola, et al 2003; Pullman et al 2003;
Mathers Dunbar et al 2004; Tellier, Niederman, et al 2004;
Fogarty, Patel, et al 2005; Mouton et al 2005) (Table 3).
Clinical and bacteriologic efficacy
Administration of telithromycin for 7–10 days in 2 open-
label studies (van Rensburg et al 2002; Carbon, Moola, et
al 2003) resulted in clinical cure rates of 92.9% and 93.6%
among PPc patients (cure rates in the mITT populations were
79.6% and 85.8%, respectively). The remaining 2 open-label
studies in which the duration of telithromycin treatment was
7 days (Fogarty, Patel, et al 2005) reported PPc clinical cure
rates of 89.6% and 93.0%, with corresponding mITT cure
rates of 83.1% and 85.4%.
In 3 of the comparative trials, a 7- to 10-day regimen of
telithromycin once daily was shown to be as clinically
effective (PPc population) as amoxicillin 1000 mg 3-times
daily for 10 days (94.6% vs 90.1%) (Hagberg et al 2002),
clarithromycin 500 mg twice daily for 10 days (88.3% vs
88.5%) (Mathers Dunbar et al 2004), and trovofloxacin
200 mg once daily for 7–10 days (90.0% vs 94.2%) (PullmanTherapeutics and Clinical Risk Management 2006:2(1) 66
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et al 2003). In the mITT populations, telithromycin clinical
success rates were 85.9%, 78.9%, and 82.0% vs 78.5%,
84.6%, and 85.6% for amoxicillin, clarithromycin, and
trovofloxacin, respectively. The fourth comparative study
demonstrated that telithromycin administered once daily for
either 5 or 7 days was as effective as clarithromycin 500 mg
twice daily for 10 days with PPc clinical cure rates of 89.3%,
88.8%, and 91.8%, respectively (Tellier, Niederman, et al
2004). The corresponding mITT cure rates were 82.4%,
82.2%, and 81.2%.
Across the 8 studies described above, a satisfactory
bacteriologic outcome was achieved in 80.0%–92.9% of
telithromycin-treated patients at the TOC visit (PP
population) (Table 3). Among patients who received a
comparator antibacterial, a satisfactory bacteriologic
outcome was achieved in 83.3%–100% of patients
(amoxicillin, 87.5%; clarithromycin, 96.4% and 83.3%;
trovafloxacin, 100%). Pooled analyses of data from the 8
CAP studies have been used to investigate the efficacy of
telithromycin in subgroups of patients, including those with
infections caused by pneumococci resistant to penicillin and/
or erythromycin (van Rensburg et al 2005), patients infected
with atypical–intracellular pathogens (Dunbar et al 2005),
and patients with pneumococcal bacteremia (Carbon, van
Resnburg, et al 2003). Among a total of 37 PP patients
infected with S. pneumoniae isolates resistant to penicillin
and/or erythromycin, 33 (89.2%) achieved clinical cure and
eradication of the causative pathogen at TOC (van Rensburg
et al 2005). The clinical success rate was also high for
telithromycin-treated patients infected with atypical–
intracellular pathogens: C. pneumoniae, 34/36 (94.4%);
M. pneumoniae, 36/37 (97.3%); and L. pneumophila,
13/13 (100%) (Dunbar et al 2005). Among telithromycin-
treated patients with documented pneumococcal bacteremia
(n = 82; PP population), clinical cure and bacterial
eradication rates were 90.2% (74/82) and 93.9% (77/82),
respectively (Carbon, van Rensburg, et al 2003).
Recent data from a randomized, open-label, comparative,
international study (Study 4015) suggest that telithromycin
may be more effective in treating CAP than a range of
commonly prescribed antibiotics, at least in areas where
pneumococcal macrolide resistance is high (Mouton et al
2005). The study was conducted in 9 countries with
documented erythromycin resistance rates ≥ 30% (Greece,
Hong Kong, Hungary, South Africa, South Korea, Spain,
Taiwan, Thailand, and Tunisia). Adults with CAP received
either telithromycin 800 mg once daily for 7–10 days or a
comparator oral antibiotic usually prescribed locally and/
or recommended by local guidelines (β-lactam, macrolide,
or fluoroquinolone). The clinical cure rate in the
telithromycin group was significantly higher than that in
the comparator group (mITT population): 86.0% vs 78.8%,
respectively (p = 0.04). The results of this trial are the first
to demonstrate superior clinical efficacy of telithromycin
over comparators.
Health outcomes
CAP-associated healthcare resource utilization data were
collected for telithromycin- and comparator-treated patients
enrolled in two of the four comparator-controlled clinical
trials (Niederman et al 2004a; Tellier, Chang, et al 2004).
The similar design of these studies and the use of a common
comparator agent (clarithromycin) allowed data from the
two studies to be pooled to investigate whether there were
any differences in overall healthcare resource utilization
associated with telithromycin for 5, 7, or 10 days vs
clarithromycin for 10 days (Niederman et al 2004b).
Although the two treatments showed equivalent clinical
efficacy, telithromycin treatment (for 5, 7, or 10 days) was
associated with significantly fewer CAP-related
hospitalizations (1.2 vs 3.6 per 100 patients) and CAP-
related days spent in hospital (8.8 vs 33.8 days per 100
patients). Similar differences were noted among subsets of
patients with risk factors for morbidity. Among patients aged
≥ 65 years, there were 0 vs 6.6 hospitalizations and 0 vs
64.5 hospital days per 100 patients receiving telithromycin
and clarithromycin, respectively. In patients with a Fine
score > II, there were 2.1 hospitalizations per 100
telithromycin-treated patients vs 9.5 hospitalizations per 100
clarithromycin patients (resulting in 15.6 vs 94.6 hospital
days per 100 patients, respectively [Niederman et al 2004b]).
Overall, CAP-related hospitalization costs were significantly
lower for telithromycin recipients, resulting in an estimated
cost saving of US$ 302 per patient.
Safety and tolerability
The safety and tolerability of telithromycin have been
evaluated in a total of 16 Phase III clinical trials, comprising
14 of the 16 studies presented in Table 3 (Study 4017 and
Study 4015 were not included in the analysis) and 2 studies
conducted in patients with tonsillitis–pharyngitis. The
safety-evaluable population included all patients who
received at least 1 dose of study medication and had at least
1 safety assessment following randomization.Therapeutics and Clinical Risk Management 2006:2(1) 70
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generally well tolerated and most adverse events (AEs) were
of mild to moderate intensity. In the 11 comparator-
controlled clinical trials, 1348 patients out of a total of 2702
(49.9%) treated with telithromycin reported at least 1
treatment-emergent AE (TEAE) compared with 48.4%
(1035/2139) of comparator-treated patients. TEAEs
considered by the investigator to be possibly related to study
medication were reported in 31.9% (861/2702) of
telithromycin-treated patients and 28.3% (606/2139) of
comparator-treated patients participating in the 11 trials. The
most frequent of these possibly related TEAEs (occurring
in >1% of patients in either treatment group) are listed in
Table 4. Overall, TEAEs of the gastrointestinal and nervous
system were the most commonly reported events possibly
related to study medication. Incidences of blurred vision
were reported more frequently with telithromycin (30/2702
[1.1%]) than with comparator antibacterials (6/2139
[0.28%]). Fifteen of the 20 cases reported in telithromycin-
treated patients were considered by the investigator to be
possibly related to study medication. The events were
generally mild in intensity and started most frequently within
the first 2 days of treatment. All cases resolved without
sequelae and no cases were reported as serious AEs. Rates
of discontinuation of study medication were similar between
telithromycin and comparator agents (4.4% and 4.3%,
respectively). Most treatment discontinuations were
attributable to gastrointestinal TEAEs, primarily diarrhea
(telithromycin 0.9%, comparators 0.6%) and vomiting
(telithromycin 0.8%, comparators, 0.5%). Clinically
noteworthy elevations in liver enzymes (eg, aspartate
aminotransferase and alanine aminotransferase) occurred
in similar proportions of telithromycin-treated (1.2% and
1.6%, respectively) and comparator-treated patients (1.3%
and 1.7%, respectively). Overall, 1.1% of patients in the
controlled Phase III trials reported treatment-emergent visual
AEs compared with 0.28% of patients who received
comparators (Aventis 2005). Visual disturbances included
blurred vision, diplopia, or difficulty focusing. Most of these
events were mild to moderate, although severe cases have
been reported; all visual AEs were reversible upon cessation
of drug treatment (Aventis 2005).
Across all 16 trials, the incidence of death was low
(telithromycin, 17/4472 [0.4%]; comparators, 9/2139
[0.4%]) and none of the deaths was considered to be related
to study medication. Similarly, the frequency of serious
TEAEs considered related to study medication was low
and comparable across treatment groups in the controlled
trials (telithromycin, 0.3% [9/2702]; comparators, 0.3%
[6/2139]).
At therapeutic doses, telithromycin was associated with
a small mean increase (1.5 milliseconds) in QTc interval.
However, QTc outlier values were uncommon and similar
in frequency to those seen with clarithromycin and
nonmacrolide antibacterials, and no excess in risk for
significant QTc prolongation was noted in telithromycin-
treated patients, including those in at-risk populations.
Post-marketing surveillance
The results of a post-marketing surveillance study conducted
in Germany (the country in which telithromycin was first
introduced in 2001) provide the first broad-ranging evidence
of the safety and effectiveness of telithromycin in routine
practice (Lorenz and Roscher 2004). Data are available for
a total of 34 929 outpatients with community-acquired RTIs
treated with telithromycin 800 mg once daily for a median
of 5 days (AECB, ABS, or tonsillitis–pharyngitis) or 7 days
(CAP). There was a high level of satisfaction with
telithromycin therapy, with 95.6% of physicians and 94.1%
of patients reported to be satisfied or very satisfied. The
overall rate of clinical cure or improvement with
telithromycin was 98.4%. Adverse drug reactions were
reported by 1.9% of patients and were predominately
gastrointestinal in nature. Serious adverse drug reactions
were observed in 32 patients (0.1%).
Rare occurrences of allergic reactions, atrial arrhythmias,
syncope (usually associated with vagal syndrome), and
exacerbations of myasthenia gravis have been reported in
the worldwide post-marketing surveillance for telithromycin
(Aventis 2005).
Table 4 Treatment-emergent adverse events (TEAEs) possibly
related to study medication reported by >1% of patients in 11
comparator-controlled trials of telithromycin
Number (%) of patients
Possibly related Telithromycin Comparators
TEAE (n = 2702) (n = 2139)
Diarrhea 270 (10.0) 171 (8.0)
Nausea 190 (7.0) 87 (4.1)
Headache 54 (2.0) 53 (2.5)
Dizziness (excluding 75 (2.8) 33 (1.5)
vertigo)
Vomiting 64 (2.4) 30 (1.4)
Loose stools 58 (2.1) 30 (1.4)
Dyspepsia 36 (1.3) 21 (1.0)
Dysgeusia 40 (1.5) 76 (3.6)
Total nr of patients 861 (31.9) 606 (28.3)
with possibly related
TEAEsTherapeutics and Clinical Risk Management 2006:2(1) 71
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Interactions with other drugs
Telithromycin, like the macrolides, is both a substrate and
an inhibitor of the CYP3A4 metabolic pathway. A number
of specific drug interaction studies have been undertaken in
humans to assess the effects of co-administration of
telithromycin with CYP3A4 inhibitors, CYP3A4 inducers,
and CYP3A4 substrates. In addition, drug interaction studies
have been conducted with several other concomitantly
prescribed drugs, including paroxetine and metoprolol,
theophylline, warfarin, digoxin, class III antiarrhythmic
agents, and oral contraceptives. The results of the drug
interaction studies are summarized in Table 5.
CYP3A4 inhibitors
The azole antifungals ketoconazole and itraconazole both
strongly inhibit hepatic CYP3A4. However, although both
ketoconazole and itraconazole moderately increased
telithromycin Cmax and AUC (Shi, Montay, et al 2005), the
extent of these increases is considered unlikely to be
clinically relevant. Grapefruit juice (components of which
inhibit intestinal, but not hepatic, CYP3A4) had no effect
on telithromycin pharmacokinetics during co-administration
(Shi, Montay, et al 2005).
Rifampicin and other CYP3A4 inducers
Rifampicin (a potent inducer of hepatic metabolic enzymes,
including CYP3A4) has been shown to reduce serum levels
of clarithromycin (Kolars et al 1992). Similarly, concomitant
administration of telithromycin with rifampicin reduced
telithromycin exposure by approximately 80% (Aventis
2005). Co-administration of the two drugs is therefore not
recommended.
CYP3A4 substrates
Administration of telithromycin with the CYP3A4 substrates
cisapride and pimozide is contraindicated owing to the
potential for prolongation of the cardiac QTc interval if
exposure to cisapride or pimozide is increased. Following
oral co-administration with the benzodiazepine midazolam,
the plasma level of oral midazolam was increased 6-fold
(Aventis 2005); patients receiving oral midazolam and
telithromycin concomitantly should therefore be monitored,
and a reduction in the midazolam dose should be considered
if necessary. In a study with healthy volunteers, Cmax and
AUC of simvastatin increased 5.3-fold and 8.9-fold,
respectively, during co-administration with telithromycin
(Aventis 2005). In a second study in healthy patients in
which simvastatin and telithromycin were administered 12
hours apart, there was much lower increase in simvastatin
Cmax and AUC (3.4-fold and 4.0-fold, respectively) (Aventis
2005). Nevertheless, it is recommended that co-adminis-
tration of telithromycin with simvastatin, lovastatin, or
atorvastatin should be avoided; if telithromycin is prescribed,
therapy with any of these statins should be suspended during
the course of treatment. Pravastatin and fluvastatin are not
extensively metabolized by CYP3A4; therefore,
telithromycin is not expected to interact with these agents.
Other drug interactions
In line with previous drug interaction studies involving
macrolides, telithromycin has been shown to exert moderate
effects on the pharmacokinetics of theophylline. The
increased exposure to theophylline when co-administered
with telithromycin may increase the incidence of gastro-
intestinal side-effects, and it is recommended that the two
drugs be given 1 hour apart (Bhargava, Leroy, et al 2002).
Although telithromycin has been observed to increase
digoxin levels, no significant changes in electrocardiogram
parameters occurred and there were no signs of digoxin
toxicity (Montay et al 2002). However, as suggested for
macrolides, digoxin side-effects or serum levels should be
monitored during concomitant administration with
telithromycin. Post-marketing reports suggest that
telithromycin could potentiate the effects of oral anti-
coagulants when the two drugs are co-administered.
Consideration should therefore be given to monitoring
prothrombin times/International Normalized Ratio (INR)
while patients are receiving telithromycin and oral
anticoagulants simultaneously (similar interactions between
warfarin and macrolides have been reported).
No clinically significant interactions have been observed
between telithromycin and antacids containing aluminum
or magnesium. In addition, telithromycin
 does not influence
the anti-ovulatory effects of oral contraceptives containing
ethinylestradiol or levonorgestrel (Scholtz et al 2000).
Conclusions
The ketolide antibacterial telithromycin demonstrates potent
activity against key common RTI pathogens, including S.
pneumoniae isolates resistant to other antibiotics and
atypical–intracellular organisms, and has a low potential to
select for or induce resistance. In European countries where
telithromycin has been available for clinical use since 2001–
2002, antibiotic surveillance data indicate that telithromycin
has retained in vitro activity against the common respiratory
pathogens, including penicillin-resistant or macrolide-Therapeutics and Clinical Risk Management 2006:2(1) 72
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resistant strains of S. pneumoniae (> 99% susceptible)
(Reinert, Felmingham, et al 2004; Reinert, Rodloff, et al
2004). Clinical data support these in vitro findings, with
results of randomized controlled studies showing
telithromycin 800 mg once daily to be as effective as current
standards of care for the treatment of ABS, AECB, and CAP.
Telithromycin displays pharmacokinetic parameters
allowing for once-daily dosing; in addition, it can be
administered in short-duration therapy for most RTI
indications, which may encourage good patient compliance.
In clinical trials, treatment with telithromycin was well
tolerated, with AEs being typically mild to moderate in
intensity, transient in nature, and occurring at rates
comparable with those seen with other first-line treatment
options. Assessment of additional healthcare resource
utilization in patients with CAP and AECB also indicates
that telithromycin may be associated with reduced rates of
hospitalization compared with standard first-line treatment
options, suggesting the potential for significant cost savings
with wider use.
In summary, based on clinical experience to date,
telithromycin is an appropriate option for the treatment of
community-acquired ABS, AECB, and mild to moderate
CAP.
Table 5 Interactions between telithromycin and commonly prescribed drugsa
Drug Interaction Comments/recommendations
CYP3A4 inhibitors
Ketoconazole Increase in TEL exposure: No clinically significant interaction
Cmax by 51%; AUC by 95%
Itraconazole Moderate increase in TEL exposure: Cmax No clinically significant interaction
by 22%; AUC by 54%
CYP3A4 inducers
Rifampicin Reduction in TEL exposure: Cmax by 79%; Co-administration not recommended
AUC by 86%
CYP3A4 substrates
Cisapride/pimozide Not tested: potential for TEL to increase Use of TEL contraindicated with cisapride and
pimozide exposure pimozide
Midazolam 6-fold increase in midazolam exposure (AUC) Midazolam dose adjustment may be necessary
Statins (simvastatin,  lovastatin, Simvastatin exposure increased 5.3-fold Suspension of simvastatin, lovastatin, or
 atorvastatin) (Cmax)/8.9-fold (AUC). atorvastatin therapy recommended if TEL is
Lovastatin and atorvastatin not  tested prescribed
CYP2D6 substrates
Metoprolol Moderate increase in exposure to metoprolol: Co-administration in patients with heart failure
~38% on Cmax and AUC, but no effect on elimination  should be considered with caution
half-life of metoprolol
Others
Theophylline Moderate increase in exposure to theophylline: To reduce GI side-effects of theophylline, drugs
~17% on Cmax and AUC should be administered 1 hour apart
Digoxin Moderate increase in exposure to digoxin Monitor digoxin side-effects or serum levels
(plasma peak and trough levels increased by 73%
and 21%, respectively) but no changes in ECG
or signs of digoxin toxicity
Warfarin No significant effects on racemic warfarin. Consider monitoring prothrombin times/INR
Post-marketing reports suggest TEL may increase
exposure to oral anticoagulants
Antacids or other agents containing No interactions
multivalent cations
Oral contraceptives Anti-ovulatory effects of oral contraceptives
containing ethinylestradiol or levonorgestrel
unaffected by TEL
aAdapted from Ciervo and Shi (2005).
Abbreviations: AUC, area under the concentration–time curve; Cmax, peak plasma concentration; CYP, cytochrome P450; ECG, electrocardiogram; GI,
gastrointestinal; INR, international normalized ratio; TEL, telithromycin.Therapeutics and Clinical Risk Management 2006:2(1) 73
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